Background. The use of antiretroviral therapy during pregnancy is important for control of maternal human immunodeficiency virus (HIV) disease and the prevention of perinatal HIV transmission. Physiological changes during pregnancy can reduce antiretroviral exposure. We studied the pharmacokinetics of rilpivirine 25 mg once daily in HIV-1-infected women during late pregnancy.
Human immunodeficiency virus type 1 (HIV-1)-infected pregnant women are commonly treated with combination antiretroviral therapy (cART) for their own health and to reduce the risk of perinatal transmission [1] .
During pregnancy, cART is aimed at maximal virological suppression and minimization of maternal and fetal adverse effects. To achieve this, the pharmacokinetic properties of antiretroviral drugs in pregnancy must be considered. It is known that pregnancy-related physiological changes can alter the pharmacokinetics of antiretroviral agents, mostly resulting in a reduction of drug exposure during pregnancy [2] . Decreased maternal antiretroviral exposure may lead to virologic breakthrough and/ or development of antiretroviral resistance, as well as increase the risk of perinatal HIV transmission [3, 4] .
Rilpivirine is a nonnucleoside reverse transcriptase inhibitor (NNRTI) registered for the treatment of HIV [5] . The standard rilpivirine dose is 25 mg once daily taken with food. It is available as an individual tablet or as fixed-dose formulation with either tenofovir disoproxil fumarate and emtricitabine, or tenofovir alafenamide and emtricitabine. As such, rilpivirine-based antiretroviral therapy is widely used due to its excellent antiviral potency, long-term efficacy, and once-daily dosing [6] . Rilpivirine is highly albumin bound (>99%), extensively metabolized by the liver, primarily by cytochrome P450 (CYP) 3A4, and <1% is eliminated as unchanged drug.
Currently, rilpivirine is recommended as a first-line [7] or alternative [8] treatment option as part of cART for HIV-1-infected patients with an RNA level <100 000 copies/mL and CD4 T-lymphocyte (CD4) count >200 cells/μL. However, there is currently no consensus on its place in pregnancy treatment guidelines, and suboptimal rilpivirine exposure during pregnancy has been reported in 2 peer-reviewed reports [9, 10] .
Given that rilpivirine has an intermediate genetic barrier to resistance, suboptimal exposure may put pregnant women at risk of virological failure [8] .
The data currently available are limited, and confirmatory studies are warranted, for the development of evidence-based treatment guidelines for rilpivirine pharmacotherapy during pregnancy. The primary objective of this study was to describe the pharmacokinetics of rilpivirine 25 mg once daily in HIVinfected pregnant women.
METHODS
Data were collected as part of an ongoing nonrandomized, open-label, multicenter, prospective, phase 4 study in HIVinfected pregnant women recruited from HIV treatment centers in Europe (pharmacokinetics of newly developed antiretroviral agents in HIV-infected pregnant women [PANNA] Network: www.pannastudy.com). This study was conducted in compliance with the principles of the Declaration of Helsinki. Informed consent was obtained from each participant before entering the study. The study was approved by the medical ethical committee for each individual center involved and by the national authorities if applicable. The study is registered at ClinicalTrials.gov under number NCT00825929. Protocol and methods have been detailed previously [11] [12] [13] [14] [15] and are summarized below.
HIV-infected pregnant women of at least 18 years of age at screening and treated with rilpivirine 25 mg once daily for at least 2 weeks before the day of first pharmacokinetic evaluation were eligible to enroll in the rilpivirine study arm. Patients were excluded if they had a past medical history or current condition that might interfere with drug absorption, distribution, metabolism, or excretion, or presented with grade III/IV anemia. Patients were also excluded if they were unable to understand the nature and extent of the study and the procedures required.
Pharmacokinetic Blood Sampling
Pharmacokinetics were evaluated based on pharmacokinetic blood sampling at 2 occasions: one in the third trimester and one at least 2 weeks postpartum. On both occasions, prior to the observed morning dose of rilpivirine, subjects consumed a standardized breakfast (650 kcal; 30 g fat). Blood samples were collected just before drug intake and at 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours after rilpivirine dosing. The blood samples were centrifuged and plasma was stored at -18°C or lower until shipment to the central laboratory for analysis.
Time-matched cord and maternal blood samples were taken at delivery to assess rilpivirine placental transfer, when feasible.
Bioanalysis of Rilpivirine in Plasma
Total rilpivirine plasma concentrations were determined using a validated liquid chromatography-tandem mass spectrometry method. The calibration curve was linear over a concentration range of 0.004 mg/L to 3.750 mg/L. The intra-and interday accuracy (% deviation) ranged from -4% to 14% and -3% to 5%, respectively. The intra-and interday precision (coefficient of variation [CV%]) ranged from 3.5 to 10.4% and 0.0% to 8.3%, respectively. Bioanalysis was performed at the Radboud University Medical Center, Department of Pharmacy laboratory. In addition, the method was externally validated through the International Interlaboratory Quality Control Program for Measurement of Antiretroviral Drugs in Plasma [16] and by the proficiency testing program of the Clinical Pharmacology Quality Assurance and Quality Control program [17] .
Safety Assessments and Viral Load
Inclusion screening consisted of medical history evaluation, physical examination, serum biochemistry, hematology and qualitative urinalysis, HIV-1 RNA load (undetectable defined as <50 copies/mL), and CD4 determination. Safety assessments were done by local laboratories. At each study-related visit, additional blood samples were taken for laboratory monitoring. At each visit, patients were asked for adverse events and use of concomitant medications. Also, data on infant birth weight, congenital abnormalities, and HIV status were collected. For infant HIV status, initial testing (at birth) was used (ie, DNA polymerase chain reaction test). Follow-up tests were not automatically reported. However, if the infection status of the infant changed, this was reported to the study team. Postpartum data on infant feeding were not collected. Current treatment guidelines in the countries involved advice against breastfeeding; hence, we expect that all infants were formula fed.
Pharmacokinetic and Statistical Analysis
Steady-state pharmacokinetic parameters were derived using a noncompartmental analysis in Phoenix 64 (Certara). Derived pharmacokinetic parameters include area under the curve over a dosing interval (AUC 0-24h ), maximum concentration (C max ), predose concentration (C 0h ), minimum observed concentration (C min ), and apparent clearance (CL/F). These parameters were determined per individual, for the third trimester of pregnancy and postpartum. For calculation of AUC 0-24h we imputed C 0h when the concentration 24 hours after dose (C 24 ) was missing. Pharmacokinetic outcomes were not available for clinicians or patients in real time.
Patients undergoing a pharmacokinetic assessment in the third trimester were included in the demographics, the safety analyses, and the descriptive statistics of the derived pharmacokinetic parameters. Pharmacokinetic parameters at third trimester and postpartum are reported as geometric means with CV%. Geometric mean ratios (GMRs) (third trimester vs postpartum) with 90% confidence intervals (CIs) are calculated based on paired pharmacokinetic parameters.
The pharmacokinetic parameters were compared by means of a bioequivalence approach [18] . The minimum amount of paired observations required for this approach is 12. In general, bioequivalence assumes that equivalent exposure leads to equivalent effects. Bioequivalence is concluded when the 90% CI for the GMR of interest is within 80%-125% limits.
In addition, we compared the number of subjects with a rilpivirine C min <0.04 mg/L in pregnancy and postpartum. This cutoff has been related to reduced virological response [19] .
Placental transfer is expressed as a ratio of the concentration in the cord plasma divided by the concentration in the maternal plasma.
RESULTS
Sixteen pregnant HIV-infected women with a median age of 29 (range, 18-36) years were included in the analysis. All patients had relatively high CD4 counts and were virologically suppressed at baseline visit. One patient was lost to follow-up after the third-trimester visit. All patients used a fixed-dose combination of rilpivirine coformulated with tenofovir disoproxil phosphate and emtricitabine. One patient additionally used ritonavir-boosted lopinavir (LPV/r). Demographics, antiretroviral therapy, and pregnancy outcomes are shown in Table 1 . Treatment adherence was self-reported and 100% up to 2 weeks prior to pharmacokinetic sampling.
Pharmacokinetics
The concentration-time profiles of rilpivirine (25 mg once daily) during pregnancy and postpartum are shown in Figure 1 . Derived individual pharmacokinetic parameters were plotted in Figure 2 and summarized in Table 2 . The subject with concomitant LPV/r, a drug that could increase rilpivirine concentrations due to CYP3A4 inhibition, showed average exposure in the third trimester and relatively high exposure postpartum. We included this patient in all analyses. Inclusion of this subject did not affect the parameter estimates (data not shown).
In the third trimester of pregnancy, the rilpivirine AUC 0-24h and C min were reduced by 45% and 49%, respectively, compared to postpartum (Table 3 ). This indicates a substantially lowered exposure during pregnancy. All GMRs and their 90% CI for AUC 0-24h , C max , C 0h , C min , and apparent clearance under steady-state conditions (CL ss /F) were outside the 80%-125% limits for bioequivalence. Moreover, 2 of 16 (13%) subjects had subtherapeutic C 0h and 4 of 16 (25%) subjects had C min <0.04 mg/L in the third trimester of pregnancy. Postpartum, no subtherapeutic levels were observed.
The elimination constant could not be derived for half of the patients during third trimester (n = 7). C 24 samples were missing for 4 individuals during third trimester and 7 individuals postpartum. In most of these cases, extrapolation to C 24 was not possible because of the missing elimination constants and therefore C 24 is not included in Table 2 Additionally, we explored the relation between the timing of the postpartum pharmacokinetic assessment (ie time after gestation) and the individual AUC 0-24h and C min ratios. No trend was observed (data not shown).
Five umbilical cord plasma samples were collected with matching maternal plasma samples at delivery. The median cord-to-maternal rilpivirine plasma concentration ratio was 0.50 (range, 0.35-0.81).
Viral Loads, Pregnancy Outcomes, and Safety
No virologic breakthrough was observed in this study. One serious adverse event, admission to the hospital because of irregular contractions, was reported and was judged not to be related to rilpivirine. In total, 13 adverse events were reported by 8 patients, including anemia (n = 3), gestational diabetes (n = 3), rectal molluscum pendulum, duodenitis, urinary tract infection, preeclampsia, hemorrhagic delivery, irregular contractions, and urticaria. None were judged to be related to the study medication. No children tested positive for HIV and no birth defects were reported, such as preterm delivery or low birth weight. No other major safety concerns were reported.
DISCUSSION
In this study, the rilpivirine exposure following standard 25 mg once-daily dosing taken with food was reduced by about 45% in the third trimester of pregnancy compared to postpartum. Lowered rilpivirine exposure during pregnancy (20%-40%) was previously observed in 2 other studies and a case report [9, 10, 20] . The results from these studies, and the current study, indicate that rilpivirine exposure is consistently lower during late pregnancy.
In this and other studies, bioequivalent rilpivirine exposure during third trimester of pregnancy and postpartum could not be concluded and the rilpivirine exposure during pregnancy was lowered [9, 20] . Even with wider limits (eg, 70%-143%) than the standard 80%-125% limits, bioequivalence could not be concluded. Moreover, in the current study all GMR 90% CIs fell outside the 80%-125% limits, indicating statistical significance and sufficient statistical power. Thus, based on the bioequivalence criteria, similar efficacy of standard rilpivirine dosing during late pregnancy cannot be assumed.
Another way of looking at pharmacokinetic endpoints is in the light of the exposure-response relationship. Looking at in vitro exposure-response measures, no subjects had concentrations below the protein-binding adjusted concentration that leads to 90% maximal response (EC 90 ) value (0.012 mg/L) [21] . The subject using ritonavir-boosted lopinavir is indicated with an asterisk. Units for each parameter are given in the y-axis titles. Abbreviations: 3T, third trimester of pregnancy; AUC 0-24h , area under the curve; C 0h , predose concentration; C max , maximum concentration; C min , minimum observed concentration; PP, postpartum. Abbreviations: AUC 0-24h , area under the curve; C 0h , predose concentration; CI, confidence interval; CL/F ss , apparent clearance under steady-state conditions; C max , maximum concentration; C min , minimum observed concentration; GMR, geometric mean ratio. [26] and based on intensive steady-state pharmacokinetic data from 15 human immunodeficiency virus-infected nonpregnant adults from Uganda [23] .
As the translation from in vitro to in vivo potency measures is not always straightforward, comparing the pharmacokinetic outcomes from this study with potency data from clinical studies may be more informative [22] . In a post hoc analysis of 645 subjects enrolled in 2 phase 3 trials, virologic response was lower in subjects with lower rilpivirine exposure. Of note is that subject eligibility for this study was beyond the current indication for rilpivirine for subjects with HIV-1 RNA <100 000 copies/mL. In this study, subjects with C 0h ≤0.04 mg/L had lower virologic response (70% vs >80% in subjects with C 0h >0.04 mg/L) [19] . In the current study, 2 of 16 (13%) subjects had subtherapeutic C 0h and 4 of 16 (25%) subjects had C min <0.04 mg/L in the third trimester of pregnancy. No subtherapeutic rilpivirine levels were observed postpartum. In addition to the bioequivalence approach and the evaluation of individual subtherapeutic rilpivirine exposure during pregnancy and postpartum, a third perspective may assist in interpreting the outcomes of our study. This perspective consists of a comparison with another clinical situation in which rilpivirine exposure is lowered-that is, coadministration of rilpivirine with rifampicin or rifabutin. Through induction of CYP450, most likely CYP3A4, rifabutin and rifampicin decrease rilpivirine exposure (AUC) by 46% and 80%, respectively. On the basis of these data, it is recommended that rifampicin should not be coadministered with rilpivirine. When coadministered with rifabutin, the rilpivirine dose should be increased to 50 mg once daily [5] . Although the rifampicin-mediated reduction in rilpivirine exposure is much greater, the reduced rilpivirine exposure observed in the current study is similar to the reported reduction in rilpivirine exposure with rifabutin. Consequently, caution is needed when considering standard 25 mg once-daily dosing during late pregnancy.
Nevertheless, despite lowered overall exposure during late pregnancy and more subtherapeutic drug levels, no detectable viral loads were observed. Two previous studies looking at the pharmacokinetics of rilpivirine during pregnancy had similar results in terms of virologic response [9, 20] . Tran et al [9] studied 32 pregnant women and found that C min was significantly lower at 15 women's study visits where HIV-1 RNA was detectable compared with 61 visits with undetectable viremia, but this was not directly related to pregnancy. Although it is tempting to compare rates of virological failure, this and the current study, were not designed nor powered to detect differences in rilpivirine pharmacodynamic endpoints (eg, viral load). The fact remains that, despite lowered rilpivirine exposure in 3 prospective cohort studies, viral suppression was mostly maintained throughout the end stage of pregnancy and no perinatal transmission was observed. This indicates that rilpivirine exposure during late pregnancy is sufficient to protect both mother and the unborn. Because all women in the current study were suppressed prior to their third trimester visit, it is likely that the exposure required to maintain suppression is lower than the exposure required to reach viral suppression, also implying that the 0.4 mg/L target concentration may be conservative for maintaining viral suppression during pregnancy.
Lower exposure during pregnancy is most likely explained by changes in albumin plasma concentrations during pregnancy and pregnancy-related CYP3A4 induction [23] . Important to note is that for the current study, only total plasma concentrations were measured. For highly albumin-bound drugs, such as rilpivirine, the total plasma concentration may decrease during pregnancy because of changes in albumin concentrations, while the unbound drug concentrations at the target site may not be affected. Nevertheless, unbound rilpivirine concentrations during pregnancy have been measured in another study [20] . The pregnancy-induced reduction in unbound rilpivirine exposure was observed to be smaller than the reduction in total rilpivirine exposure. Still, unbound rilpivirine exposure during pregnancy was not bioequivalent (based on the 80%-125% limits) to the unbound rilpivirine exposure postpartum. Although no detectable viral loads were observed, this again indicates that similar efficacy of standard rilpivirine dosing during pregnancy cannot be assumed.
In the current study, the postpartum assessment served as the control for the nonpregnant situation, and was mostly taken between 4 and 6 weeks after delivery, but also at 3 weeks postpartum. Although this design provides a powerful intrasubject comparison, it can be questioned to what extent pregnancy-induced physiological processes are normalized 3 or 4 weeks postpartum. Fortunately, previous work indicated that this time span is sufficient for relevant physiological processes to normalize, and no remaining effects on pharmacokinetics were observed [24] . As expected on the basis of these data, we did not observe a trend between the timing of the postpartum pharmacokinetic assessment and the individual pharmacokinetic ratios. Consequently, this has not impacted the results of this study.
The rilpivirine cord-to-maternal plasma concentration ratio found in this study is 0.50 and comparable to ratios previously observed for rilpivirine [9, 10, 20] . This indicates that fetal rilpivirine exposure at term is moderate compared to maternal exposure. Rilpivirine is classified as a pregnancy category B drug, indicating that no adequate and well-controlled studies of rilpivirine in pregnant women have been conducted to assess fetal safety, but that animal studies have shown no evidence of relevant embryonic or fetal toxicity or an effect on reproductive function [25] . In our study, we did not observe any birth defects or abnormal pregnancy outcomes. In addition to this, rilpivirine was well-tolerated by all women during pregnancy and postpartum.
Based on the current body of evidence, the US treatment guideline recommends cART consisting of 2 nucleoside reverse transcriptase inhibitors and either a ritonavir-boosted protease inhibitor (atazanavir or darunavir) or an integrase inhib-itor (raltegravir) for antiretroviral-naive pregnant women [1] . Although we did not observe virologic breakthrough or perinatal HIV transmission, we do not recommend that rilpivirine 25 mg once daily be added to this list of preferred treatment options because of the markedly decreased exposure during pregnancy. Future research could focus on the evaluation of a higher rilpivirine dose during pregnancy.
Overall, the results from this study suggest that rilpivirine 25 mg once daily may be an alternative treatment option for HIV-1-infected pregnant women who are virologically suppressed, in settings where therapeutic drug monitoring and/ or close viral load monitoring are feasible to detect suboptimal antiretroviral therapy. 
